10/12（一）12:45 Chatting with you 【Periapical Bone Regeneration: Synthetic bone substitute in endodontic surgery】｜Dr. Liao Guo-Han Even amidst a busy schedule, don't miss the chance to recharge your professional knowledge! If you are a dentist looking to master the concepts of endodontics and key clinical application techniques, this is a session you won't want to miss! ▍Seminar Details Date: October 12 (Monday) Time: Starts promptly at 12:45 PM (Online access opens at 12:15 PM) Platform: Microsoft Teams (Live Stream) ▍How to Register: Join the Horien Biotech Official LINE Account Fill in your details to receive the live stream link. https://lin.ee/zec8yGZ

HORIEN Biochemical Technology Gains Further International Attention Three Thai FDA Class 4 Approvals and U.S. Patent Achievement Featured by Multiple International Media Outlets September 8, 2026 HORIEN Biochemical Technology Co., Ltd. (TPEx: 7814) continues to advance its international market expansion. The Company has recently achieved significant progress in both the Thai medical device market and its international intellectual property strategy. Related news was distributed through the PR Newswire global news release network and subsequently published or syndicated by international and Asian media platforms, including Yahoo Finance and Kosmo Digital. This further enhances the international visibility of the HORIEN brand and Taiwan’s biomedical materials technology. Three Collagen-Based Medical Devices Receive Thai FDA Class 4 Approvals One of the key developments highlighted by international media is the formal approval of three collagen-based medical devices developed by HORIEN Biochemical Technology under the Thai Food and Drug Administration (Thai FDA) Class 4 classification: “Horien” Collagen Bone Graft Matrix “Horien” Collagen Matrix “Horien” Extracellular Membrane The three products cover a range of medical applications, including dentistry, surgery, and tissue care. Completion of the approval process for these high-risk medical devices in Thailand marks an important milestone in HORIEN’s expansion into Southeast Asia. It also establishes a foundation for the Company to develop distribution partnerships, professional education programs, and local market support services in Thailand. HORIEN is currently engaging with Thai medical device partners that possess experience in dental, surgical, and regenerative medicine distribution channels. Through localized market strategies and professional support, the Company aims to gradually establish long-term and stable partnerships. Biodegradable Ureteral Stent Receives U.S. Patent In addition to expanding into Southeast Asian markets, HORIEN’s independently developed Biodegradable Ureteral Stent has received a U.S. invention patent, demonstrating the Company’s continued efforts to extend its biomedical materials technologies into additional medical fields. From its existing dental and collagen-based biomedical materials products to technologies related to urological medical devices, HORIEN continues to invest in materials science, manufacturing processes, and medical device product development. Through patents, regulatory approvals, and international market partnerships, the Company is gradually building a more comprehensive biomedical materials technology platform. International Media Exposure Enhances HORIEN Brand Visibility Following the official release of the international news on September 8, 2026, the announcement was published across multiple international and Asian media outlets and financial information platforms, including: PR Newswire APAC https://www.prnewswire.com/apac/news-releases/taiwans-horien-accelerates-global-footprint-achieves-three-thai-fda-class-4-approvals-and-secures-us-patent-for-biodegradable-ureteral-stent-302870921.html?utm_source=chatgpt.com   PR Newswire Asia / PR Newswire Asia Archive https://en.prnasia.com/story/archive/5040113_AE40113_0?utm_source=chatgpt.com   PR Newswire APAC – Thai https://en.prnasia.com/releases/apac/125327298-0.shtml?utm_source=chatgpt.com   Yahoo Finance US https://finance.yahoo.com/healthcare/articles/taiwans-horien-accelerates-global-footprint-020000039.html?utm_source=chatgpt.com   Yahoo Finance Australia https://au.finance.yahoo.com/news/taiwans-horien-accelerates-global-footprint-020000039.html?utm_source=chatgpt.com   Yahoo Finance Singapore https://sg.finance.yahoo.com/news/taiwans-horien-accelerates-global-footprint-020000039.html?utm_source=chatgpt.com   Taiwan News https://www.taiwannews.com.tw/en/news/6435499?utm_source=chatgpt.com   BioSpectrum Asia https://www.biospectrumasia.com/news/27/28338/taiwans-horien-achieves-three-thai-fda-class-4-approvals-and-secures-us-patent-for-biodegradable-ureteral-stent-.html?utm_source=chatgpt.com   The Malaysian Reserve https://themalaysianreserve.com/2026/09/08/taiwans-horien-accelerates-global-footprint-achieves-three-thai-fda-class-4-approvals-and-secures-u-s-patent-for-biodegradable-ureteral-stent/?utm_source=chatgpt.com   Kosmo Digital https://www.kosmo.com.my/2026/09/08/taiwans-horien-accelerates-global-footprint-achieves-three-thai-fda-class-4-approvals-and-secures-u-s-patent-for-biodegradable-ureteral-stent/   PR News Thailand https://www.prnewsthailand.com/prnewswire/th/view/69234   Asia Business Newswire / Siam News Network https://www.siamnews.net/pr-news/taiwans-horien-accelerates-global-footprint-achieves-three-thai-fda-class-4-approvals-and-secures-u-s-patent-for-biodegradable-ureteral-stent/?utm_source=chatgpt.com   Quamnet https://www.quamnet.com/post/kSVo-mTwQXAhMJtjfgF5O   The Store by South China Morning Post https://store.scmp.com/pages/news?filter=28425&rkey=20260907AE40113 In addition to the platforms listed above, the announcement continues to be distributed through international news networks across different regional markets, enabling more healthcare industry professionals, distribution partners, and international audiences to follow the development of Taiwan’s biomedical materials industry. From Taiwan to the Global Market: Deepening Southeast Asian Expansion Thailand is one of the key markets in HORIEN’s Southeast Asian expansion strategy. The approval of three products under the Thai FDA Class 4 classification not only represents an important regulatory foundation for entering the Thai market, but also enables the Company to further develop local distribution partnerships and market opportunities. HORIEN General Manager Hsin-Yu Ho stated that Thailand is an important part of HORIEN’s Southeast Asian market development strategy. In the next phase, the Company will focus on identifying partners with established clinical distribution networks and a strong commitment to professional medical education, with the goal of building long-term partnerships with substantial market depth. Looking ahead, HORIEN will continue to focus on independent research and development, biomedical materials technology, international regulatory strategy, and local market partnerships. The Company will deepen its presence in Thailand and Southeast Asia while actively pursuing additional international certifications and patent opportunities for its products, bringing biomedical materials technologies from Taiwan to more markets around the world. HORIEN Biochemical Technology — From Taiwan to the Global Healthcare Market. 復原接受

2026.08_Obtaining US patent: Biodegradable Double-J Stentand Method Of Manufacturing The Same, Patent Application No.: 18/444,629.

Horien Biotech (7814) was transferred from the Emerging Stock Market to the OTC Market today (16th). With its overseas expansion and new product development continuing, analysts are optimistic about the company's sustained growth momentum.  Horien Biotech stated that its June revenue increased by 209.29% year-on-year, benefiting from increased demand in Taiwan, the United States, and overseas markets. Regarding its overseas expansion, the company obtained three Class 4 medical device marketing authorizations in Thailand in July, and Class III medical device licenses in the Philippines and Vietnam are expected to be obtained soon, strengthening its presence in the Southeast Asian market. Furthermore, its bio-ink products are expected to be exported to the European market by the end of the year.  In terms of R&D, Horien Biotech's independently developed biodegradable ureteral stent has obtained a Taiwanese invention patent and plans to apply for patents in the United States, Europe, and China. Currently, sample development has been completed and the product has entered the animal testing phase. The company pointed out that the product is expected to improve the problem of traditional ureteral stents requiring a second surgery for removal. In addition, collagen regeneration patches developed using decellularization technology have entered the trial production stage, targeting the surgical and orthopedic tissue repair market.  Regarding supply chain development, its subsidiary, Shengli Biotechnology, has signed memorandums of understanding and cooperation agreements with Taiwan Sugar Corporation and Taiwan Livestock Corporation to establish a supply chain for animal-derived raw materials for medical devices that complies with ISO 13485 and ISO 22442 standards, ensuring the supply of high-end collagen medical device raw materials.  Chairman Tsai Kuo-Tien stated that listing on the OTC market is a significant milestone for the company. Moving forward, the company will continue to deepen its existing markets in dentistry and surgery, and promote the development of high-end medical device products and overseas markets. With the acquisition of international certifications and the progress of new product development, the company expects to drive medium- to long-term operational growth. Report Link: Horien Biotech Lists on the OTC Market Today; Certification Obtained in Thailand, Bio-inks Expand into Europe, Aiming for Overseas Growth Mnews

Horien Biotech (7814), a leading domestic manufacturer of high-end collagen medical devices, listed on the OTC market on the 16th at NT$28.45 per share. The stock price reached NT$32.15 in early trading, a 13.01% increase, initiating a honeymoon period. Horien Biotech Chairman Tsai Kuo-Tien stated that the listing is a significant milestone in the company's development history. In the future, the company will continue to deepen its global market penetration by leveraging top-grade medical-grade raw materials and groundbreaking high-end medical devices, building upon its existing dental and surgical channels.  Horien Biotech, with its strong R&D capabilities and deep technological barriers, has recently delivered outstanding results in revenue performance, international certifications, global market expansion, and the establishment of a top-tier biomedical raw material supply chain. Driven by continued strong demand in the US, Taiwan, and overseas markets, Horien Biotech achieved a remarkable 209.29% revenue increase in June. This success is attributed not only to strong fundamentals but also to breakthrough progress in its overseas expansion.  On July 7th, Horien Biotech successfully obtained three high-risk (highest level, Class 4) medical device market access licenses in Thailand, successfully entering the ASEAN high-end medical device market. Furthermore, the Philippines and Vietnam are also expected to obtain Class III medical device licenses soon, signifying that its important strategic layout in the Southeast Asian market is nearing completion. Moreover, the company's highly anticipated bio-ink innovative product is planned for official export to the European market by the end of this year, extending its international footprint from Asia to Europe and America, and is expected to see a surge in global revenue contributions.  In the research and development of high-end innovative medical devices, Horien Biotech has achieved a disruptive world-class breakthrough. The company's independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and is expected to soon obtain invention patents in the United States, Europe, and China. Currently, this innovative product has successfully completed sample development and has been officially delivered for animal testing. Report Link: Horien Biotech's stock price surged on its first day of trading, with intraday gains exceeding 10% Economic Daily News / Yan Ya-Fang

High-end collagen medical device manufacturer Horien Biotech (7814) listed on the OTC market today (16th) at NT$28.45, with its share price surging as much as 13% at the opening. Benefiting from continued strong demand in the US, Taiwan, and overseas markets, Haichang's revenue increased by 55% year-on-year in the first half of this year. With the continued expansion of regenerative medicine applications and the gradual advancement of several new products, revenue growth momentum is expected to continue in the second half of the year, with the company aiming for profitability for the full year. Horien Biotech has established its R&D advantages through "polymorphic collagen processing technology" and "decellularization technology," enabling it to precisely adjust material properties according to different clinical needs, balancing structural strength, ease of operation, and biocompatibility, while retaining key factors that promote tissue repair. This technology platform not only creates a clear competitive barrier but also helps the company continue to upgrade towards the high-value medical device market, improve the overall product portfolio's gross profit structure, and strengthen its differentiated competitive advantage over its peers.  In addition to the steady growth of its existing products, Horien Biotech is actively developing high-end medical devices, targeting the global market with large-scale potential. Horien Biotech's independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and is expected to receive invention patents in the US, Europe, and China soon. This product not only solves the clinical pain point of traditional stents requiring secondary surgery for removal but also targets a pristine blue ocean market worth billions of US dollars with no competition. The market widely regards it as a crucial growth engine for Horien Biotech's future, potentially propelling the company into a new phase of rapid growth.  Meanwhile, the collagen regeneration patch developed using its core "advanced decellularization technology," primarily targeting surgical and orthopedic tissue repair, has recently entered the trial production stage, providing a strong profit foundation for its medium- to long-term product line.  In overseas markets, Horien Biotech recently obtained three high-risk (highest level, Class 4) medical device marketing authorizations in Thailand, successfully entering the ASEAN high-end medical device market. Furthermore, it is expected to obtain Class III medical device licenses in the Philippines and Vietnam soon, signifying that its important strategic layout in the Southeast Asian market is nearly complete. Furthermore, the company's highly anticipated bio-ink innovative product is also planned for official export to the European market by the end of this year, extending its international footprint from Asia to Europe and the United States, and its global revenue contribution is expected to see a surge.  With the continued expansion of regenerative medicine applications and the gradual advancement of several new products, collagen-based sheet products are expected to receive certification as early as the fourth quarter and begin contributing to revenue. Analysts are optimistic about continued revenue growth in the second half of the year, maintaining a strong performance for the full year, and striving for profitability. Report Link: Horien Biotech's stock price surged as much as 13% on its first day of trading on the over-the-counter market, with new products and export sales driving continued strong momentum for the second half of the year Investment Weekly / He Mei-Ru